OBI Pharma, Inc.

4174

TW0004174008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 03:30:00 30/05/2024 am IST			5-day change	1st Jan Change
58.6 ^TWD	-0.34%		-0.68%	-15.56%

30/05	OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA	CI
15/05	OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

OBI Pharma, Inc.(TPEX:4174) dropped from FTSE All-World Index

March 20, 2023 at 09:30 am IST

OBI Pharma, Inc.(TPEX:4174) dropped from FTSE All-World Index (USD)

Latest news about OBI Pharma, Inc.

OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA	30/05	CI
OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	10/05	CI
OBI Pharma, Inc. Announces OBIGEN TFDA Clearance of IND Application for A Phase II Human Clinical Trial	02/05	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners	11/03	CI
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial	31/01	CI
OBI Pharma, Inc. Announces OBI-992 TROP2 ADC Has Been Granted by US FDA to Proceed to Phase I/II Human Clinical Trial	03/01	CI
OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023	20/12	CI
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA	01/12	CI
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
OBI Pharma, Inc. Announces Head Office Address Change	06/11	CI
OBI Pharma, Inc. Announces Internal Audit Officer Changes	06/11	CI
OBI Pharma, Inc. Announces CFO Changes	06/11	CI
OBI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
OBI Pharma, Inc. Announces Executive Changes	07/23/07	CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman	27/23/27	CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director	27/23/27	CI
OBI Pharma, Inc. Announces COVID-19 Vaccine, BCVax, Has Been Granted by TFDA to Proceed to Phase I Clinical Trial	02/23/02	CI
OBI Pharma Appoints Heidi Wang as Chief Executive Officer	02/23/02	CI
OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
OBI Pharma, Inc. Files the Application of Phase I Human Clinical Trial for COVID-19 Vaccine, BCVax, to TfDA	31/23/31	CI
OBI Pharma, Inc.(TPEX:4174) dropped from FTSE All-World Index	20/23/20	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15/23/15	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15/23/15	CI

OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OBI PHARMA, INC.	-15.56%	415M
MODERNA, INC.	+52.36%	58.06B
IQVIA HOLDINGS INC.	-3.86%	40.53B
LONZA GROUP AG	+36.78%	38.99B
CELLTRION, INC.	-12.01%	26.56B
ICON PUBLIC LIMITED COMPANY	+14.13%	26.7B
ALNYLAM PHARMACEUTICALS, INC.	-21.62%	18.98B
BIO-TECHNE CORPORATION	+0.21%	12.17B
MEDPACE HOLDINGS, INC.	+25.96%	11.92B
UNITED THERAPEUTICS CORPORATION	+23.02%	12B